In our study, we investigated VEGF-A, the receptors VEGFR-1-3 and their major co-receptors NRP-1 and NRP-2 in a cohort of 147 WHO grade II and III meningioma patients in order to elaborate potential therapeutic targets. The gene discussed is FLT1; the disease is meningioma.